ARTICLE | Clinical News
PMI-001: Phase IIb data
August 31, 2009 7:00 AM UTC
A completer analysis of 62 patients from a double-blind, active-controlled, U.S. Phase IIb trial showed that 60 mg PMI-001 thrice daily met the primary endpoint of an ACR20 response at 6 months compar...